In any industry, there's a moment when the question stops being "does this technology work?" and starts being "who controls it?" For liquid biopsy, that moment arrived in Q1 2026.

Abbott's $21 billion acquisition of Exact Sciences — which closed on March 23 — is the headline number. But it's the rest of the quarter that makes it a signal, not an outlier. In the span of twelve weeks, GRAIL submitted the final module of its Galleri PMA application, Natera filed a Signatera companion diagnostic PMA for bladder cancer, Congress signed the MCED Medicare coverage bill into law, and Guardant's 360 CDx won FDA approval as a companion diagnostic for BRAF V600E-mutant colorectal cancer.

Any one of these would be a noteworthy quarter. Together, they mark the point where liquid biopsy crossed from clinical validation into infrastructure.

The Consolidation Thesis

Abbott didn't pay $21 billion for a liquid biopsy company. It paid for a diagnostics platform that happens to include liquid biopsy — along with Cologuard, Oncotype DX, and a pipeline that touches screening, treatment selection, and monitoring.

That's the point. The acquirers aren't buying single assays anymore. They're buying positions across the testing continuum — from asymptomatic screening (MCED) through therapy selection (companion diagnostics) to post-treatment surveillance (MRD). The companies that own multiple nodes along that continuum will define how oncology testing works for the next decade.

Guardant's multi-year collaboration with Merck follows the same logic. It's not just a CDx deal — it's a pharma company embedding a diagnostics partner into its entire oncology portfolio. And BillionToOne's $314 million Nasdaq IPO confirms that public markets are buying the thesis too.

What We're Seeing

Dexter's platform data tells a parallel story. Liquid biopsy-related projects have more than doubled since 2021, making it one of our most consistently growing categories. MRD monitoring demand has more than doubled year-over-year, and ctDNA-related projects have roughly tripled over the past three years.

But the nature of the questions is shifting. Early projects — circa 2020-2022 — were overwhelmingly "help us understand the landscape." They were mapping exercises: which tests exist, how do they compare, what's the clinical evidence base.

The projects we're seeing now are different. Clients are asking about reimbursement strategy, lab integration workflows, and competitive positioning within specific tumor types. The conversations have moved from "should we invest in liquid biopsy?" to "how do we win in liquid biopsy?"

That shift — from technology scouting to commercial execution — mirrors what happened with NGS about five years earlier. And it's accelerating faster than most industry watchers expected.

The MRD-MCED Divide

One of the clearest patterns in our data is the divergence between two liquid biopsy use cases that are often grouped together but face very different futures.

MRD monitoring is on the faster track to clinical integration. Natera's Signatera CDx PMA submission for muscle-invasive bladder cancer is the latest proof point, following strong data at ASCO GU showing utility across genitourinary cancers. SAGA Diagnostics launched its Pathlight MRD test in colorectal cancer, and Personalis added real-time ESR1 resistance mutation tracking to its NeXT Personal platform. The clinical question — "is there residual disease?" — is binary enough that the evidence bar, while still high, is navigable.

Multi-cancer early detection (MCED) faces a harder road, though the policy infrastructure is finally catching up. The Miller-Meeks bill enabling Medicare coverage of FDA-approved MCED tests — starting in 2029 — removes the largest single reimbursement obstacle. GRAIL's Galleri PMA filing is the furthest along, while Caris partnered with Everlywell to launch a whole-genome sequencing-based MCED test in H1 2026.

The challenge with MCED isn't sensitivity or specificity — it's the downstream clinical workflow. When a blood test says "you might have cancer somewhere," the health system needs to know what to do next. That workflow doesn't fully exist yet, and building it requires the kind of cross-functional expertise — oncology, primary care, health economics, payer relations — that's hard to assemble.

The AI Layer

Underneath the headline deals, a quieter shift is happening in how liquid biopsy data gets interpreted. An AI-powered approach called M-PACT demonstrated 92% accuracy in classifying pediatric brain tumors via ctDNA methylation patterns in cerebrospinal fluid — a result that matters because pediatric brain tumors are notoriously difficult to biopsy surgically.

This points to a broader trend: liquid biopsy is becoming less about the assay and more about the computational layer that sits on top of it. As the underlying sequencing becomes commoditized, the differentiation shifts to algorithms, training data, and clinical validation cohorts. It's the same pattern that reshaped digital pathology and genomics before it.

Guardant's 28 abstracts at AACR 2026 lean heavily into this direction, with tumor typing and multiomic approaches that depend more on computational interpretation than on the liquid biopsy itself.

What This Means

For pharma strategy teams: The Abbott-Exact Sciences deal redraws the competitive map. If your CDx strategy was built around partnering with an independent diagnostics company, check whether that company is still independent. The window for standalone CDx partnerships is narrowing.

For diagnostics investors: The category is consolidating around platform players, not single-assay companies. The question to ask isn't "does this test work?" — it's "does this company own enough of the testing continuum to matter at scale?"

For clinical operations teams: MRD-guided therapy is moving from research to reimbursed reality faster than most implementation timelines assume. If you're not piloting ctDNA monitoring in at least one tumor type by end of year, you're likely behind the adoption curve.

For health economics teams: The MCED Medicare coverage bill creates a three-year runway to figure out downstream workflows before coverage kicks in. That clock is ticking.

The common thread is that liquid biopsy is no longer a bet on the technology. It's a bet on the business model — and Q1 2026 made clear which models are winning.

Dexter connects life sciences decision-makers with the experts who shape the field. If you work in oncology diagnostics, molecular pathology, or precision medicine and want to share your expertise on an ad hoc basis, learn more about joining our network.